Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LTRN Lantern Pharma	$3.06 -2.4%	$3.44	$2.55 ▼ $6.40	$32.95M	1.63	64,599 shs	15,056 shs
ONCY Oncolytics Biotech	$0.35 -2.9%	$0.52	$0.35 ▼ $1.53	$30.59M	1	571,026 shs	299,183 shs
PLUR Pluri	$4.49 -1.7%	$4.59	$3.33 ▼ $7.13	$35.13M	0.77	15,882 shs	3,212 shs
SLXN Silexion Therapeutics	$1.03 +6.8%	$0.93	$0.58 ▼ $41.85	$8.87M	0.06	5.18 million shs	574,202 shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LTRN Lantern Pharma	+9.06%	-6.57%	-10.32%	-20.76%	-47.92%
ONCY Oncolytics Biotech	-2.96%	-9.33%	-38.44%	-44.85%	-66.57%
PLUR Pluri	+0.22%	+1.56%	-1.06%	+4.82%	-21.48%
SLXN Silexion Therapeutics	-0.41%	-2.61%	+6.67%	-10.28%	+95,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
LTRN Lantern Pharma	2.6218 of 5 stars	3.5	2.0	0.0	0.0	3.3	0.8	1.3
ONCY Oncolytics Biotech	1.2162 of 5 stars	3.4	2.0	0.0	0.0	1.5	0.0	0.0
PLUR Pluri	0.2987 of 5 stars	0.0	3.0	0.0	0.0	1.7	0.8	0.0
SLXN Silexion Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
LTRN Lantern Pharma	3.00	Buy	$25.00	718.33% Upside
ONCY Oncolytics Biotech	2.75	Moderate Buy	$4.33	1,124.11% Upside
PLUR Pluri	0.00	N/A	N/A	N/A
SLXN Silexion Therapeutics	3.00	Buy	$5.00	387.80% Upside

Current Analyst Ratings Breakdown

Latest SLXN, ONCY, PLUR, and LTRN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/21/2025	ONCY Oncolytics Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
5/16/2025	ONCY Oncolytics Biotech	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
4/2/2025	LTRN Lantern Pharma	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$25.00
3/20/2025	SLXN Silexion Therapeutics	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$9.00 ➝ $5.00
3/10/2025	ONCY Oncolytics Biotech	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $3.00
3/10/2025	ONCY Oncolytics Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
3/10/2025	ONCY Oncolytics Biotech	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$6.00 ➝ $5.00

(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
LTRN Lantern Pharma	N/A	N/A	N/A	N/A	$3.76 per share	N/A
ONCY Oncolytics Biotech	N/A	N/A	N/A	N/A	$0.27 per share	N/A
PLUR Pluri	$1.03M	34.04	N/A	N/A	($0.42) per share	-10.70
SLXN Silexion Therapeutics	N/A	N/A	$0.70 per share	1.46	($6.63) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
LTRN Lantern Pharma	-$15.96M	-$1.84	N/A	N/A	N/A	N/A	-56.91%	-51.17%	8/14/2025 (Estimated)
ONCY Oncolytics Biotech	-$20.56M	-$0.29	N/A	N/A	N/A	N/A	-141.15%	-84.73%	7/30/2025 (Estimated)
PLUR Pluri	-$20.89M	-$5.53	N/A	∞	N/A	-3,551.49%	-2,778.13%	-83.61%	N/A
SLXN Silexion Therapeutics	$260K	N/A	0.00	∞	N/A	N/A	N/A	-249.43%	6/17/2025 (Estimated)

Latest SLXN, ONCY, PLUR, and LTRN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	LTRN Lantern Pharma	-$0.49	-$0.42	+$0.07	-$0.42	N/A	N/A
5/14/2025	Q1 2025	ONCY Oncolytics Biotech	-$0.09	-$0.06	+$0.03	-$0.06	N/A	N/A
5/13/2025	Q3 2025	PLUR Pluri	N/A	-$0.94	N/A	-$0.94	N/A	$0.43 million
5/13/2025	N/A	SLXN Silexion Therapeutics	N/A	-$0.26	N/A	-$0.26	N/A	N/A
3/27/2025	Q4 2024	LTRN Lantern Pharma	-$0.51	-$0.54	-$0.03	-$0.54	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
LTRN Lantern Pharma	N/A	N/A	N/A	N/A	N/A
ONCY Oncolytics Biotech	N/A	N/A	N/A	N/A	N/A
PLUR Pluri	N/A	N/A	N/A	N/A	N/A
SLXN Silexion Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
LTRN Lantern Pharma	N/A	8.31	8.31
ONCY Oncolytics Biotech	N/A	2.99	2.99
PLUR Pluri	4.44	5.04	5.04
SLXN Silexion Therapeutics	N/A	0.85	0.85

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
LTRN Lantern Pharma	28.62%
ONCY Oncolytics Biotech	6.82%
PLUR Pluri	16.59%
SLXN Silexion Therapeutics	10.95%

Insider Ownership

Company	Insider Ownership
LTRN Lantern Pharma	7.31%
ONCY Oncolytics Biotech	0.10%
PLUR Pluri	10.20%
SLXN Silexion Therapeutics	33.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
LTRN Lantern Pharma	20	10.79 million	10.00 million	Optionable
ONCY Oncolytics Biotech	30	86.42 million	85.42 million	Not Optionable
PLUR Pluri	150	7.83 million	6.28 million	Optionable
SLXN Silexion Therapeutics	N/A	8.69 million	1.07 million	N/A

SLXN, ONCY, PLUR, and LTRN Headlines

Recent News About These Companies

Silexion Therapeutics Corp (SLXN)’s RNAi Therapy Blocks 90% of Colorectal Tumors

May 30 at 3:52 AM | msn.com

Silexion Therapeutics Announces Groundbreaking Preclinical Results: SIL204 Shows Strong Efficacy in Pancreatic, Colorectal, and Lung Cancers

May 29 at 5:50 PM | finance.yahoo.com

Critical Analysis: BioNTech (NASDAQ:BNTX) versus Silexion Therapeutics (NASDAQ:SLXN)

May 26, 2025 | americanbankingnews.com

Silexion's SIL204 Completes Key Preclinical Studies In KRAS-Mutant Cancers

May 23, 2025 | nasdaq.com

Silexion Therapeutics Receives Nasdaq Delisting Notice

May 23, 2025 | tipranks.com

PESG Research Report: A Review of Silexion Therapeutics' Innovative KRAS-Driven Cancer Treatment

May 22, 2025 | globenewswire.com

Silexion Therapeutics Corporation Registered Shs

May 22, 2025 | markets.businessinsider.com

Silexion Therapeutics Completes Key Preclinical Studies Exploring SIL204’s Potential Impact on Colorectal and Lung Cancer

May 21, 2025 | finance.yahoo.com

Silexion Therapeutics Completes Preclinical Study on SIL204 for Expanded KRAS-Driven Cancer Therapies

May 21, 2025 | quiverquant.com

Silexion Therapeutics Completes Key Preclinical Studies Exploring SIL204's Potential Impact on Colorectal and Lung Cancer

May 21, 2025 | globenewswire.com

Silexion Therapeutics Corp: Silexion Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 14, 2025 | finanznachrichten.de

Silexion Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 13, 2025 | globenewswire.com

Silexion Therapeutics enters collaboration with Catalent

April 25, 2025 | markets.businessinsider.com

Silexion Therapeutics Enters Strategic Collaboration with Catalent to Advance SIL204 Development for KRAS-Driven Cancers

April 23, 2025 | quiverquant.com

Silexion Therapeutics Announces Collaboration with Global Therapeutics Leader Catalent on Advanced siRNA Formulation Development & Clinical Manufacturing Activities

April 23, 2025 | globenewswire.com

Silexion Therapeutics announces expanded development plan for SIL204

March 28, 2025 | markets.businessinsider.com

Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data

March 28, 2025 | globenewswire.com

Silexion announces completion of expanded development plan for SIL204

March 21, 2025 | markets.businessinsider.com

Silexion Therapeutics price target lowered to $5 from $9 at Maxim

March 21, 2025 | markets.businessinsider.com

Silexion Therapeutics Corp. Announces Expanded Development Plan for SIL204 at NeauxCancer 2025 Conference

March 21, 2025 | quiverquant.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLXN, ONCY, PLUR, and LTRN Company Descriptions

Lantern Pharma NASDAQ:LTRN

$3.06 -0.08 (-2.40%)

As of 12:19 PM Eastern

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Further, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. Lantern Pharma Inc. has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

Oncolytics Biotech NASDAQ:ONCY

$0.35 -0.01 (-2.85%)

As of 12:21 PM Eastern

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Pluri NASDAQ:PLUR

$4.49 -0.08 (-1.66%)

As of 12:14 PM Eastern

Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.

Silexion Therapeutics NASDAQ:SLXN

$1.02 +0.07 (+6.77%)

As of 12:24 PM Eastern

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time